U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ACHIRAL
Molecular Formula C21H18N4O4S
Molecular Weight 422.457
Optical Activity NONE
Defined Stereocenters 0 / 0
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of HS-173

SMILES

CCOC(=O)C1=CN=C2C=CC(=CN12)C3=CC(NS(=O)(=O)C4=CC=CC=C4)=CN=C3

InChI

InChIKey=SEKOTFCHZNXZMM-UHFFFAOYSA-N
InChI=1S/C21H18N4O4S/c1-2-29-21(26)19-13-23-20-9-8-15(14-25(19)20)16-10-17(12-22-11-16)24-30(27,28)18-6-4-3-5-7-18/h3-14,24H,2H2,1H3

HIDE SMILES / InChI
Molecular Formula C21H18N4O4S
Molecular Weight 422.457
Charge 0
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE

Description
Curator's Comment: Description was created based on several sources, including https://www.ncbi.nlm.nih.gov/pubmed/27793006

HS-173 is a potent PI3Kα inhibitor with IC50 of 0.8 nM. HS-173 inhibited the PI3K signaling pathway, and showed anti-proliferative effects on cancer cells. Also, HS-173 induced cell cycle arrest at the G(2)/M phase and apoptosis. In addition, HS-173 decreased the expression HIF-1α and VEGF which play an important role in angiogenesis. This effect was confirmed by the suppression of tube formation and migration assay in vitro. Furthermore, HS-173 diminished blood vessel formation in the Matrigel plug assay in mice. Therefore, HS-173 is considered as a novel drug candidate to treat cancer patients.

Originator

Korea Advanced Institute of Science and Technology
1
Curator's Comment: Lee H. et al, Korea Advanced Institute of Science and Technology, Korea.

Approval Year

Unknown
139594
Targets

Targets

Primary TargetPharmacologyConditionPotency
Inhibitor
8297
 0.8 nM [IC50]
Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Primary
Preclinical
Unknown

Approved Use

Unknown
Primary
Preclinical
Unknown

Approved Use

Unknown
PubMed

PubMed

TitleDatePubMed
HS-173, a novel PI3K inhibitor suppresses EMT and metastasis in pancreatic cancer.
2016 Nov 22
Patents

Patents

WO2016025656A1
3

Sample Use Guides

In Vivo Use Guide
Mice: In xenograft and orthotopic pancreatic tumor models, mice were treated by HS-173 intraperitoneally at a dose of 10 mg/kg
Route of Administration: Intraperitoneal
In Vitro Use Guide
When pancreatic cancer cells were treated with various concentrations (0.1- 10 uM) of HS-173, it reduced the cell viability in a dose and time-dependent manner. In particular, 1 uM of HS-173 inhibited the cell growth by 40-50% in Miapaca-2 and Aspc-1 cells at 48 h.
Substance Class Chemical
Created
by admin
on Sat Dec 16 18:08:59 GMT 2023
Edited
by admin
on Sat Dec 16 18:08:59 GMT 2023
Record UNII
2758X982JL
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
HS-173
Code English
IMIDAZO(1,2-A)PYRIDINE-3-CARBOXYLIC ACID, 6-(5-((PHENYLSULFONYL)AMINO)-3-PYRIDINYL)-, ETHYL ESTER
Systematic Name English
Code System Code Type Description
CAS
1276110-06-5
Created by admin on Sat Dec 16 18:08:59 GMT 2023 , Edited by admin on Sat Dec 16 18:08:59 GMT 2023
PRIMARY
PUBCHEM
52936849
Created by admin on Sat Dec 16 18:08:59 GMT 2023 , Edited by admin on Sat Dec 16 18:08:59 GMT 2023
PRIMARY
FDA UNII
2758X982JL
Created by admin on Sat Dec 16 18:08:59 GMT 2023 , Edited by admin on Sat Dec 16 18:08:59 GMT 2023
PRIMARY
Related Record Type Details
PHOSPHATIDYLINOSITOL 4,5-BISPHOSPHATE 3-KINASE CATALYTIC SUBUNIT ALPHA ISOFORM
TARGET -> INHIBITOR
IC50
Related Record Type Details
Structure of HS-173
ACTIVE MOIETY
NIH
NCATS
PRIVACY ACT
ACCESSIBILITY
DISCLAIMER
HHS VULNERABILITY DISCLOSURE
For language access assistance, contact the NCATS Public Information Officer
National Center for Advancing Translational Sciences (NCATS),
6701 Democracy Boulevard, Bethesda MD 20892-4874 • 301-594-8966